Physician profile
Timothy Malone
NPI 1225008832
$7,265.53
in general payments reported to CMS, 2019-2025
28 companies · $926 in 2025
The $926 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $3,466 · 2021: $362 · 2022: $209 · 2023: $520 · 2024: $801 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,479.46 | 2019-2020 | |
| Abbvie INC. | $582.15 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $426.15 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.41 | 2023-2025 | Caplyta |
| Lundbeck LLC | $379.98 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $278.37 | 2019-2022 | |
| Bausch Health US, LLC | $270.34 | 2022-2025 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $262.75 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $216.46 | 2019-2025 | Lybalvi, Aristada |
| Noven Therapeutics, LLC | $141.71 | 2024-2025 | Xelstrym, Secuado |
| Lilly USA, LLC | $121.59 | 2020 | |
| Axsome Therapeutics, INC. | $82.66 | 2022-2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $74.73 | 2019 | |
| Idorsia Pharmaceuticals US INC | $71.71 | 2023-2025 | Quviviq, Quviviq |
| Eisai INC. | $70.93 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $68.13 | 2023-2024 | Azstarys |
| Adlon Therapeutics L.P. | $51.60 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.29 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $45.71 | 2019-2024 | Hetlioz, Fanapt |
| Tris Pharma INC | $42.23 | 2022-2023 | Dyanavel Xr |
| Almatica Pharma LLC | $36.82 | 2024-2025 | Loreev Xr |
| Shire North American Group INC | $26.89 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.61 | 2023 | |
| Collegium Pharmaceutical, INC. | $22.55 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $18.73 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.12 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.74 | 2019 | |
| Neos Therapeutics, LP | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.